Diagnostic value of ischemia-modified albumin in acute coronary syndrome and acute ischemic stroke

Abstract

Objective: To investigate diagnostic value of ischemia-modified albumin (IMA) levels in patients applying to emergency with symptoms of acute coronary syndrome (ACS) and acute ischemic stroke (AIS). Methods: Two patient groups (ACS and AIS) and a control group were constituted. The study was discontinued upon reaching 30 patients in each group. Following patient approval at the initial visit, a total of 10 ml venous blood sample was obtained from all patients with a high clinical suspicion of ACS and AIS. The Troponin I and the IMA levels were determined in the blood samples. Results: Statistically significant higher IMA values were determined in the patient groups compared to the control group (p<0.001 for both groups). No statistically significant correlation was found between the IMA and the Troponin I values in the ACS and the AIS groups (p>0.05 for both groups). The sensitivity of IMA was 83% and 87% for ACS and AIS, respectively. The specificity of IMA was 90% and 87% for ACS and AIS, respectively. Conclusion: The sensitivity and specificity values, determined according to the optimal cut-off values in the groups demonstrated that IMA could be a useful diagnostic marker in ACS and AIS patients.

Effect of different doses of pregabalin on skeletal muscle ischaemia-reperfusion injury in rats

“…It has been shown previously that IMA level estimated in blood serum sample has a prognostic value for acute ischemic stroke (40). Also, it is reported that IMA level increases in early ischemia and remains high (41). In our study, IMA was signifi cantly higher in the IR group than in the Control, Pregabalin 50 and 200 mg groups.…”

Evaluation of Oxidative Stress in Women with Polycystic Ovarian Syndrome as Represented by Serum Ischemia Modified Albumin and Its Correlation with Testosterone and Insulin Resistance

“…Recent studies have demonstrated that significantly higher IMA levels are found in patients with cardiac ischemia, metabolic syndrome, hyperlipidemia, and diabetes mellitus (7-10). Moreover, Ertekin et al (25) investigated the diagnostic value of IMA levels in patients with acute coronary syndrome and ischemic stroke symptoms and concluded that IMA could be a useful diagnostic marker in acute coronary syndrome and ischemic stroke. In a large series of breast cancer patients, IMA was regarded as a potential novel marker for diagnosing doxorubicin-induced myocardial injury by predicting long-term impairment of cardiac function (26).…”

A New Marker for Ischemia: Ischemia-modified Albumin

“…Erken teşhis ve tedavi mortalite ve morbiditeyi azaltır (12) . AKS'nin gelişiminde farklı evrelerin saptanması için birçok kardiyak belirteç tarif edilmiştir.…”

“…Klasik kardiyak biyokimyasal belirteçler yüksek duyarlılık ve spesifikliğe sahip olmakla birlikte bu belirteçlerin yükselişi ataktan saatler sonra olmaktadır. AKS'nin erken teşhisi için yeni çalışılan belirteçler kolin, İMA, kalp tipi yağ asiti bağlayıcı protein (H-FABP) ve N-terminal B tip natriüretik peptid (NT-proBNP)'dir (2,12) . Bunlardan yalnızca İMA rutin kullanım için lisanslı, duyarlı, ucuz ve iskemiyi erken saptamaktadır (2,4) .…”

“…AKS ve akut iskemik inme için İMA duyarlılığı %83, %87 ve özgüllüğü ise %90, %87 idi. İMA'nın avantajları düşük fiyat, hızlı sonuç ve kolay uygulamadır ve gelecekte klinikte pratik ve güçlü belirteç olarak kullanılacaktır (12) . Son çalışmalar göstermiştir ki egzersiz sonrası İMA seviyeleri yalnızca AKS'de değil stabil koroner arter hastalarında da iskemiyi saptamada kullanılır (22) .…”